Abiomed's Impella Shows Heart Function, Symptom Improvements For High-Risk PCI Patients

Abiomed Inc's ABMD Restore EF study demonstrated that Impella-supported high-risk percutaneous coronary intervention (PCI) leads to significant improvements in left ventricular ejection fraction (LVEF), angina symptoms, and heart failure symptoms at follow-up.
A 29% relative improvement from baseline LVEF (n=251, p<0.0001), with a significantly greater improvement in LVEF for those who had complete revascularization.
Significant improvement in heart failure symptoms was observed, with an overall 76% reduction in heart failure symptoms.
Significant improvement in angina symptoms, with an overall 97% reduction in angina symptoms.
Participants with higher baseline LVEF (greater than 45%) also experienced significant symptomatic improvement, similar to patients with lower LVEF.
Restore EF and the PROTECT III study further demonstrate the safety and benefits.
PROTECT III shows reduced MACCE rates compared to PROTECT II (15.1% vs. 21.9%) when Impella is used to achieve more complete revascularization in a single setting for high-risk PCI patients.
Operators from the community and academic centers demonstrated low major bleeding rates of 2.5% in the Restore EF study and 1.8% in the PROTECT III study when contemporary best practices were followed.
Price Action: ABMD shares are down 1.41% at $290.90 during the market session on the last check Tuesday.